Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma (NCT03023046), a na phase 2 study. The primary outcome is Number of Participants With Morphological Complete Response Rate.

2. Clinical Question

The study asks whether adults with acute lymphoblastic leukemia or lymphoblastic lymphoma treated with front-line dose-adjusted etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin achieve morphological complete response within 4 cycles of study therapy. It is a phase II study of a single treatment group, not a randomized comparison with a control group. The registry record identifies the intended outcome and its definition, but does not report how many participants achieved it.

3. Trial Design

This is a phase II, single-group study with no masking. The registry lists the study as completed, with enrollment of 54. The study began on 2017-02-23 and had primary completion on 2021-05-20. Its stated focus is DA-EPOCH as front-line therapy for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma.

The treatment description specifies etoposide, doxorubicin, and vincristine sulfate by intravenous infusion over 96 hours on days 1-4; cyclophosphamide by intravenous infusion over 1 hour on day 5; and prednisone by mouth twice daily on days 1-5. Participants who are Ph+ are described as also receiving imatinib mesylate or dasatinib by mouth daily. The registry’s description ends before giving further details about that additional treatment. The intervention list also includes rituximab and laboratory biomarker analysis, but the available arm description does not establish which participants received rituximab or explain how biomarker analysis was used.

Because there is no comparator group, the study can describe outcomes among participants receiving the treatment regimen, but it cannot directly estimate how those outcomes differ from outcomes under another treatment. The registry record does not report randomization, masking, a control arm, eligibility details beyond the stated conditions and adult population, or the statistical plan used for the primary outcome. These missing details limit interpretation of how participants were selected and how the intended analysis was to be conducted.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: 54 patients were consented and enrolled onto the study. 53 patients completed the study. 1 patient was not evaluable due to early treatment discontinuation.

6. Primary Endpoint

The registry lists the primary outcome as Number of Participants With Morphological Complete Response Rate, measured over Within 4 cycles of study therapy.

The primary endpoint is the number of participants with morphological complete response within 4 cycles of study therapy. The registry defines morphological complete response using bone marrow aspirate morphology and blood counts: fewer than 5% blasts by morphology, an absolute neutrophil count >1000/uL, and a platelet count >100,000/uL. All listed criteria are part of the endpoint definition.

This kind of endpoint captures whether participants meet a specified disease-response state during a stated treatment window. It is a count outcome: it records participants meeting the definition rather than measuring the degree of change in a continuous laboratory value. A response rate would ordinarily relate the number meeting the definition to an analysis population, but the registry record does not report the primary response count, a denominator for the primary analysis, or a response rate. Enrollment alone does not establish how many participants were assessed for this endpoint.

As a general statistical point, a clearly defined response endpoint makes the outcome rule explicit, but interpretation still depends on the assessment population, timing, handling of missing assessments, and analysis method. Those details are not reported in the registry record. The timeframe is specified as within 4 cycles, but the record does not state how response assessments were handled if a participant did not complete that window.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes a phase II, single-group study with no masking. It lists no statistical analyses for the posted outcomes. The endpoint is a count of participants with a defined event, and the registry states that morphological complete response is assessed within 4 cycles of study therapy. No primary-outcome estimate, confidence interval, p-value, or analysis population is reported in the registry record.

What does a count endpoint represent?

In general, a count endpoint records how many people meet a specified event definition. A count is not automatically a rate: interpreting it as a rate requires knowing the relevant population or denominator. The registry identifies enrollment of 54 participants, but does not say how many were included in the primary-outcome analysis or report the number meeting the response criteria. It would therefore be inappropriate to derive a response rate from enrollment or to treat enrollment as the endpoint denominator.

The endpoint is also tied to a defined observation window. A response within 4 cycles is not interchangeable with a response measured at another time. General endpoint interpretation depends on consistent assessment timing and a stated rule for participants without an assessment in the window. Such handling is not reported in the registry record.

What would a confidence interval tell a reader?

In general, a confidence interval expresses uncertainty around an estimate under the assumptions of the analysis. For a response proportion, it can show how compatible the observed data are with a range of underlying response frequencies. Its width is influenced by the amount of information and the analysis method. A confidence interval does not remove bias from a non-comparative design, and it cannot be interpreted without knowing the estimate and the population analyzed. No confidence interval for the primary endpoint is reported in the registry record.

A p-value, in general, assesses how incompatible the data are with a specified statistical null model, under the assumptions used. It is not the probability that a treatment works, nor a measure of the size or clinical importance of an effect. A p-value is not reported for the primary endpoint. The registry record also does not report a hypothesis or statistical test for that endpoint.

What does the single-group design allow?

In general, a single-group study can describe outcomes observed among participants receiving a regimen. It does not create a concurrent comparison that controls for differences between treatment groups. An observed outcome may reflect treatment, participant characteristics, the course of disease, other care, or a combination of influences. Randomization can support a more direct comparison by balancing factors across groups on average; this study is not listed as randomized and has no separate comparator. The absence of a comparator does not make descriptive results meaningless, but it limits causal interpretation.

How should the planning assumptions be understood?

The record describes a planning illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. It says that the effect to detect is a stated fraction of the observed effect. These are assumptions for a planning calculation, not a description of this single-group study’s design. The record does not report the resulting sample-size values, and it does not report an observed primary effect from which a reader could assess the illustration. Planning sample sizes are not observed power and do not establish how likely a completed study was to detect an effect.

In general, over-dispersion matters when observed count variability exceeds what a chosen model expects; ignoring it can make uncertainty estimates too optimistic. That concept is relevant only if a count model and its assumptions are stated. The registry record does not report a model for the primary count endpoint, a dispersion estimate, or an analysis of over-dispersion. No model-based result should be inferred from the endpoint type alone.

Likewise, general analyses of overall survival or event-free survival require methods that account for follow-up time and participants whose event status is not observed through the end of follow-up. The registry lists these as secondary outcomes but does not report their estimates, censoring details, or analysis methods. It is not possible to reconstruct such analyses from the outcome names alone.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Ph+ Subjects", "Ph- Subjects")
n      <- c(28, 25)
events <- c(27, 20)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Ph+ Subjects  28  27  96.4  81.7  99.9  82.3  99.4  82.2  99.2
ARM  Ph- Subjects  25  20  80.0  59.3  93.2  60.9  91.1  60.6  91.0

11. Multiplicity, Missing Data and Analysis Populations

The registry lists one primary outcome and secondary outcomes of adverse events, overall survival, and event-free survival. It does not report a statistical plan describing how these outcomes were tested, whether hypotheses were prespecified, or whether any adjustment for multiple comparisons was planned. The multiplicity strategy is therefore not reported in the registry record.

In general, examining several outcomes or multiple analyses can increase the chance of a false-positive finding if each is interpreted as confirmatory without accounting for the set of tests. Methods for addressing multiplicity depend on the study’s aims and analysis plan. Since no inferential results or analysis plan are reported for these outcomes, it is not possible to determine whether multiplicity was addressed or how any result should be classified as confirmatory or exploratory.

The registry record does not report the number of participants assessed for the primary endpoint, the number with missing response assessments, or the method used to handle missing data. It also does not state whether the analysis population was defined by enrollment, treatment received, evaluability, or another rule. These details matter because the endpoint is a participant count within a specified treatment window; missing assessments could affect which participants contribute to an analysis.

Enrollment is reported as 54, while the safety record lists 53 at risk. The record does not explain the relationship between those figures. They should not be treated as interchangeable denominators, and the difference should not be interpreted as a particular reason for exclusion or missingness. No primary-outcome denominator can be inferred from either figure.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: febrile neutropenia (26.4%), sepsis (17.0%), enterocolitis (3.8%), intracranial hemorrhage (3.8%), mucositis oral (3.8%).

The safety record lists a treatment group with 53 participants at risk, 32 participants affected by serious adverse events, 14 affected by other adverse events, and 18 deaths. The registry does not explain the relationship between these categories, whether participants could appear in more than one category, or whether events were judged related to treatment. The deaths are recorded in the safety data; the record does not establish their causes or attribution.

The most frequently listed serious-event terms are febrile neutropenia (26.4%) and sepsis (17.0%). Enterocolitis, intracranial hemorrhage, oral mucositis, and upper gastrointestinal hemorrhage are each listed as 3.8%. These are percentages attached to named serious-event terms in the registry record; the record does not give the corresponding event counts or explain the denominator for those percentages. They should not be interpreted as percentages of all participants without a stated denominator.

In general, adverse-event summaries describe recorded events under the study’s reporting rules, not necessarily events caused by the treatment. A participant may experience more than one event, and categories may overlap unless the reporting method says otherwise. The registry does not provide enough detail to resolve these issues or to compare safety with another regimen. The safety figures therefore describe the posted record, not a causal or comparative safety estimate.

13. What the Result Does, and Does Not, Mean

The study provides a registry record for a completed phase II evaluation of DA-EPOCH in adults with acute lymphoblastic leukemia or lymphoblastic lymphoma. It specifies the primary response endpoint and the criteria used to define morphological complete response. It also lists secondary outcomes and reports selected safety information. These details clarify what the study set out to assess and what safety events were recorded.

However, the registry record does not report the primary response count or response rate, and it does not report a statistical analysis of that endpoint. It also does not report results for overall survival or event-free survival. Without those results, the record cannot show the observed magnitude or precision of the primary outcome, and it cannot support an efficacy comparison.

The single-group design further limits what outcomes can mean causally. Even if a response result were available, an outcome among treated participants would not constitute a randomized comparison with another regimen. General explanations of uncertainty, response counts, and non-comparative designs describe statistical principles; they are not additional results from this study.

The serious adverse-event information is descriptive and has no comparator in the registry record. It does not establish that the regimen caused the listed events, and it does not establish how safety compares with another approach. The percentages for serious-event terms are reported without a stated denominator or corresponding counts, so their precise interpretation is limited.

Overall, the registry record supports a description of the design, intended endpoint, regimen, and selected safety entries. It does not support a conclusion about the size of the primary response outcome, its statistical uncertainty, or a causal treatment effect. The missing results and analysis details are not evidence that the outcome was favorable or unfavorable; they leave those questions unanswered in the registry record.

14. Why This Trial Matters Statistically

This study illustrates how a registry entry can make the intended clinical question and endpoint definition visible while leaving the central outcome estimate unavailable. The response criteria are explicit: bone marrow morphology and blood counts are combined to define morphological complete response, and the assessment window is within 4 cycles of study therapy. That precision helps readers understand what outcome was intended to be counted.

At the same time, an endpoint definition is not an outcome result. Without the number of participants meeting the definition, the analysis population, and a measure of uncertainty, a reader cannot assess the observed response frequency or how precisely it was estimated. This distinction is central to clinical statistics: a well-specified measure supports interpretation, but does not replace reporting the data and analysis.

The single-group design also makes the study useful for illustrating the boundary between description and comparison. Outcomes in a treated group can describe what was recorded in that group, but cannot provide the direct treatment contrast available from a comparable control group. The registry’s allocation and model fields identify that limitation rather than leaving readers to assume a randomized comparison.

Finally, the record shows why safety summaries require careful reading. Participant-level counts and percentages for named serious-event terms are not equivalent, and a registry entry needs to clarify denominators, overlap, attribution, and follow-up for fuller interpretation. Here, several of those details are not reported. The statistical lesson is to keep the endpoint definition, design, analysis population, uncertainty, and safety denominators distinct when interpreting a trial record.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpreting this trial record is that the primary outcome result is not reported. The registry defines morphological complete response and its timeframe, but gives no observed count, response rate, confidence interval, or test result. It also does not report the number assessed for response or how missing assessments were handled. The primary endpoint therefore cannot be quantified from the record.

The single-group design has no concurrent comparator, and the study is listed as unmasked. This limits causal interpretation and leaves no like-for-like control comparison. The registry does not report a statistical analysis plan, the model used for the primary count, or the analysis population. It also does not report results for the listed secondary survival outcomes.

The safety record reports 53 at risk, whereas enrollment is listed as 54; the record does not explain this difference. The serious-event terms are given as percentages without corresponding counts or a stated denominator. The record does not clarify overlap between event categories, event attribution, or the cause of the recorded deaths. These limits prevent more detailed comparative or causal interpretation of the safety information.

The treatment description for participants who are Ph+ ends before giving complete details, and the intervention list includes items not explained in the arm description. The registry record does not report the role of rituximab or laboratory biomarker analysis in the described treatment group. These gaps constrain reconstruction of the treatment received and do not justify assumptions about exposure or analysis.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma — NCT03023046.
• Registry record last updated 2022-07-13; status last verified 2022-06.
• Results first posted 2022-07-13.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

NCT03023046 is a completed phase II, single-group study of front-line DA-EPOCH for adults with acute lymphoblastic leukemia or lymphoblastic lymphoma. Enrollment is listed as 54; the study start date is 2017-02-23 and primary completion is 2021-05-20. The primary endpoint is the number of participants with morphological complete response within 4 cycles, defined using bone marrow morphology and blood counts.

The registry record does not report the primary response result, its analysis population, or an inferential analysis. It lists adverse events, overall survival, and event-free survival as secondary outcomes, but provides no results for the survival outcomes. The safety data list 53 at risk, 32 with serious adverse events, 14 with other adverse events, and 18 deaths, along with percentages for selected serious-event terms. The relationship among safety categories, attribution, and denominators for the term percentages is not reported in the registry record.